Roche is on a roll: For the second time in less than a year, the company has scored FDA clearance for a pair of assays that can be used together to help spot signs of Alzheimer’s disease. The duo ...

Roche has received US Food and Drug Administration (FDA) 510(k) clearance for additional cerebrospinal fluid (CSF) assays for Alzheimer’s disease (AD), supporting timely diagnosis and treatment ...

In a recent study published in the journal Nature Medicine, a group of researchers assessed if a precise blood test matches or surpasses traditional cerebrospinal fluid (CSF) tests in detecting ...

CHICAGO, April 25, 2025 /PRNewswire/ -- Belay Diagnostics, a CLIA/CAP accredited laboratory focused on the development and commercialization of molecular diagnostics targeting central nervous system ...

Fujirebio's Lumipulse® G pTau217/β-Amyloid 1-42 Plasma Ratio test has the potential to shorten the Alzheimer's disease diagnostic journey and enable earlier intervention through its accessibility and ...

Roche announced June 27 that the U.S. FDA has issued 510(k) clearance for the company's CSF Aβ42/total-tau assay to be used for the diagnosis of Alzheimer’s disease in people aged 55 and older. The ...

This article was produced in partnership with the Davos Alzheimer’s Collaborative by Scientific American Custom Media, a division separate from the magazine’s board of editors. Henry, a carpenter in ...